Compare HBM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBM | SNN |
|---|---|---|
| Founded | 1927 | 1856 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Mining | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.3B |
| IPO Year | 2005 | 2002 |
| Metric | HBM | SNN |
|---|---|---|
| Price | $29.99 | $29.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $25.00 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 3.9M | 1.4M |
| Earning Date | 05-01-2026 | 03-16-2026 |
| Dividend Yield | 0.07% | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | $8.58 |
| Revenue Next Year | $14.54 | $5.60 |
| P/E Ratio | ★ $21.47 | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.48 | $28.56 |
| 52 Week High | $32.15 | $38.79 |
| Indicator | HBM | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 69.58 | 41.12 |
| Support Level | $22.79 | N/A |
| Resistance Level | $30.02 | $31.18 |
| Average True Range (ATR) | 0.99 | 0.46 |
| MACD | 0.31 | -0.16 |
| Stochastic Oscillator | 98.53 | 21.08 |
Hudbay Minerals Inc is a copper-focused critical minerals company with three long-life operations and a pipeline of copper growth projects in Canada, Peru, and the United States. Its operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada), and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the company, which is complemented by gold, zinc, silver, and molybdenum production. Hudbay's growth pipeline includes the Copper World project and the Mason project in the USA, and the Llaguen project in Peru. The company's reportable segments are: Peru, which generates the maximum revenue, Manitoba, British Columbia, and Arizona. Geographically, it generates maximum revenue from China and Canada.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.